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Tumour staging in cancer patients generally entails a multimodality imaging approach.
Whole-body (WB) imaging techniques may, however, be more time- and cost-effective than
a multimodality approach. 2-Fluorine-18-fluoro-2-deoxy-D-glucose positron emission
tomography (18FDG-PET), computed tomography (CT) and hybrid positron emission tomog-
raphy and computed tomography (PET/CT) are the most established WB modalities,
although new techniques, amongst which diffusion-weighted magnetic resonance imaging
(DWI), are emerging. This review aims to evaluate the current evidence for WB-DWI in
oncology, to discuss its potential for the WB staging of (colo)rectal cancer and to relate it
to the established WB techniques.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
When patients are diagnosed with a malignant tumour, imag-
ing plays a key role in tumour staging and generally entails an
evaluation of the primary tumour site, as well as the most
likely sites for distant metastases. In patients with colorectal
cancer, detection of synchronous distant metastases during
primary staging is specifically relevant, since early treatment
(chemotherapy and/or surgery) can improve survival.1 In
these patients, staging consists of a combination of a chest
X-ray (or chest computed tomography (CT)) plus a CT, Mag-
netic resonance imaging (MRI) or ultrasound of the liver and
abdomen.2–4 Recently, whole-body (WB) imaging techniques10; fax: +31 (0)43 387 69
.H. Beets-Tan).
the Elsevier OA license.are being suggested as a potentially more time- and cost-
effective alternative to such a multimodality approach. The
most established whole-body staging techniques are CT, 2-
Fluorine-18-fluoro-2-deoxy-D-glucose positron emission
tomography (18FDG-PET) and hybrid positron emission
tomography and computed tomography (PET/CT). There are,
however, some shortcomings to these techniques, amongst
which are patient’s exposure to ionising radiation and limita-
tions in spatial and contrast resolution.5,6 Considering these
drawbacks, MRI could potentially be beneficial, although its
role for whole-body staging has so far not frequently been ex-
plored. This is mainly due to the long image acquisition times
required when the whole-body needs to be covered with MRI.09.
Fig. 1 – Image display of whole-body diffusion-weighted
images (WB-DWI). Whole-body diffusion-weighted images
are generally obtained by acquiring several separate DWI
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onance (MR) imaging techniques is now in evolution, one of
the most promising being diffusion-weighted MR imaging
(DWI). DWI has shown great potential for the detection of var-
ious malignancies throughout the body and can also be used
as a one-stop-shop imaging tool for whole-body tumour stag-
ing.7,8 Furthermore, DWI is a non-invasive technique that
does not require the use of ionising radiation or contrast
agents and can easily be added to a standard clinical MRI pro-
tocol. Because MRI – in many countries – is part of the stan-
dard staging work-up for rectal cancer patients, the use of
MRI + DWI as a one-stop-shop imaging tool could be of partic-
ular interest for this specific patient group.
This article aims to review the current evidence for whole-
body diffusion-weighted MR imaging in oncology, to discuss
its potential for the staging of (colo)rectal cancer and relate
it to the established whole-body imaging techniques: CT,
18FDG-PET and PET/CT.stacks [a] covering different parts of the thoraco-abdominal
region. The image greyscale is inverted [b] and the images
are combined as maximum intensity projection (MIP)
reconstructions for 3D display. This example shows the
sagittal [c] and coronal [d] WB-DWI reconstructions of a
female patient with a large tumour in the rectum (*) and a
metastatic lymph node located just proximal from the
tumour (arrow). Because the spleen (s) is an organ with a
relatively high cellular density, it generally shows high
signal on WB-DWI. For anatomical reference, the DWI
images are evaluated together with an anatomical T2-
weighted magnetic resonance imaging [e].2. Diffusion-weighted MR imaging
An in-depth discussion of the physics of diffusion-weighted
MRI is beyond the scope of this article. For a more extensive
overview we, therefore, refer the reader to related arti-
cles.7,9,10 In summary, the signal in DWI is derived from differ-
ences in random water proton movement within tissues,
which is mainly dependent on tissue cellularity, the integrity
of cell membranes and viscosity of fluids. In tissues with a
normal or low cellularity, water protons can diffuse relatively
freely which can be detected as an attenuation of the signal
intensity on DWI. Conversely, malignant tumours are gener-
ally hypercellular and contain many intact cell membranes,
which results in restricted water diffusion and a remaining
high signal on DWI. The sensitivity to diffusion is obtained
by applying two bipolar diffusion-sensitising gradients to a
standard T2-weighted spin echo sequence. The diffusion-sen-
sitivity can be varied by adjusting the ‘b-factor’, which is a
combination of the gradient duration, gradient amplitude
and the time interval between the two gradients. The higher
the b-value, the greater the signal attenuation from moving
water protons. By visually analysing the relative signal atten-
uation between images obtained at different b-factors, differ-
ences in water diffusion can be used for tissue
characterisation and identification of pathologic lesions.
DWI images obtained with high b-values make the signal of
malignant tumours stand out compared to the suppressed
background signal and have been shown useful for a better vi-
sual detection of (small) malignant tumours, for example in
the liver and prostate.11–13 In addition to visual DWI evalua-
tion, the diffusion characteristics of tissues can also be mea-
sured quantitatively as the ‘apparent diffusion coefficient’
(ADC). ADC is measured by plotting the logarithmic signal
attenuation against the applied b-factors. The slope of this
plotted line can be used as a quantitative measurement of
water diffusion; the ADC. The use of ADC has been exploited
for lesion characterisation. Malignant lesions, for example in
the liver, prostate, breast and head & neck region, can be dis-
tinguished because of differences in ADC values compared to
benign lesions.14–17 In addition to lesion characterisation,studies in rectal cancer, colorectal hepatic metastases and
brain tumours have suggested that tumour ADC measure-
ments can also be used as a biomarker for treatment response
and may predict the response to treatment at an earlier stage
than morphological changes occur.18–25 Compared to other
functional imaging techniques, DWI is advantageous in that
it does not require the use of ionising radiation or MR contrast
agents and it can easily be implemented into a standard MRI
protocol. In 2004, Takahara et al. introduced an interesting
new concept of DWI, called DWIBS (diffusion-weighted
whole-body imaging with background body signal suppres-
sion), which made it possible to obtain high quality 3D diffu-
sion images of the whole-body during free breathing. These
whole-body images can be displayed in an inverse greyscale
to resemble the image display of PET (Fig. 1).263. Pitfalls in DWI image interpretation
3.1. Qualitative (visual) image interpretation
An important limitation in the visual evaluation of DWI is the
fact that not only malignant tumours, but also several benign
lesions (e.g. abscesses) and normal anatomical structures,
such as the spinal cord, spleen, prostate and lymph nodes
may show high signal on DWI and may erroneously be inter-
preted as malignant tumour (Figs. 1 and 2).27 Furthermore,
since DWI sequences are typically based on T2-weighted
E U R O P E A N J O U R N A L O F C A N C E R 4 7 ( 2 0 1 1 ) 2 1 0 7 –2 1 1 6 2109imaging, high signal on DWI is not necessarily caused by re-
stricted water diffusion, but may also be due to prolonged
T2-relaxation times (e.g. fluid showing high signal on T2W-
MRI), a phenomenon known as ‘T2 shine through’. Hence,
knowledge of the normal anatomy and morphology is crucial
when analysing DWI and diffusion images will need to be
interpreted in combination with anatomical imaging. Differ-
ent studies have suggested that combined assessment of
DWI together with anatomical T2-weighted and/or T1-
weighted images can be beneficial to diminish interpretation
errors of DWI, for example in the evaluation of cystic liver le-
sions and skeletal metastases.28,29
The evaluation of lymph nodes on DWI is particularly chal-
lenging. Due to the high cellularity (and thus restricted diffu-
sion) of lymphoid tissue, DWI is a very sensitive technique for
the detection of lymph nodes. However, benign and malig-
nant nodes may show equally high signal on DWI, making it
difficult to stage the visualised nodes (Fig. 2). For visual eval-
uation of nodes on DWI, we will thus have to rely on the same
criteria as applied on morphological images, mainly being
size and homogeneity of signal.
3.2. Quantitative (ADC) image interpretation
Studies, mainly in head and neck and gynaecological tu-
mours, have shown more promising results for quantitative
evaluation of ADC in the discrimination between benign
and malignant lymph nodes.17,30 However, other studies
focussingmainly on ADC for pelvic lymph node evaluation re-
ported no additional benefit for ADC.31,32 A general limitation
of quantitative (ADC) evaluation for lesion characterisation is
that benign and malignant lesions can show overlapping ADCFig. 2 – Lymph node imaging on WB-DWI. Sagittal WB-DWI
[a] and 18FDG-PET [b] images of a 62 year old male patient
with massive metastatic nodal spread along the abdominal
aorta (arrows). For comparison, the sagittal WB-DWI in [c]
shows an example of a 26 year old healthy female volunteer
in whom pronounced lymph nodes are also visible in the
pelvic and axillary region (arrowheads). Since healthy
lymph nodes have a high cellular density they will show
high signal on DWI, similar to metastatic nodes and may
thus harbour a risk for false positive findings.values, which may restrict the use of ADC for the discrimina-
tion of malignancies in daily clinical practise.14,33 ADC values
are also dependant on variations in MR equipment and DWI
sequence parameters. Efforts are, therefore, being made to
standardise DW imaging protocols in order to minimise these
effects. Presently, ADC quantification is not widely applied in
whole-body studies, because it is fairly time consuming and
image quality may be reduced to compensate for the rela-
tively long scan times needed to image the whole body.
4. Current evidence for whole-body DWI in
oncology
4.1. Search strategy and selection criteria
The Pubmed and Medline databases were searched for all
English, Dutch and German language original articles pub-
lished between 1990 and November 2010, using the following
search terms: ‘whole-body’, ‘diffusion-weighted imaging’,
‘cancer’, ‘tumour’, ‘detection’ and ‘staging’. Studies were se-
lected when the following inclusion criteria were met: (1) a
DWI sequence covering the body was applied, (2) the main
study question was the detection/staging of malignant tu-
mour using WB-DWI, (3) a clear description of the applied
standard reference was provided, and (4) sensitivity and/or
specificity was provided or could otherwise be extracted from
the study data. One reviewer (DMJL) checked the titles and ab-
stracts of the identified studies in order to select studies
potentially meeting the inclusion criteria. Additional studies
were traced by checking the reference list of the selected
studies. The reviewer then studied full text copies of the se-
lected studies to decide which studies finally met the inclu-
sion criteria.
4.2. Results
Twenty-seven eligible studies were identified, of which 11
were excluded for the following reasons: full text copies of
the articles could not be retrieved,34–39 no English/Dutch/
German language,40 the study focus was technical DWI
improvement rather than tumour detection,41,42 sensitivity
and/or specificity could not be extracted,43 the study focused
on the detection of tumour within a specific organ in stead of
whole-body tumour detection.44
The vast majority of the included WB-DWI studies focused
on a visual evaluation of DWI for malignant tumour detection.
The main findings of these studies are provided in Table 1.
Several authors focussed on WB-DWI for the detection of
bone metastases, mostly originating from prostate and breast
cancers45–48 All of these authors reported a high sensitivity,
ranging between 82% and 96%. Nakanishi et al. reported as
an additional benefit of WB-DWI that both osseous and extra-
osseous tumour lesions (i.e. lymph nodes) could be evaluated
within one single examination. Nevertheless, results were
limited, as sensitivity for detection of metastatic lymph nodes
was only 46%.46 Because tumour detection was the main fo-
cus in most studies, specificity has been scarcely reported
and results are conflicting. Whereas Gutzeit et al. reported a
high specificity of 99%, Heusner et al. found an overall speci-
ficity of 67% for M-staging in breast cancer. Moreover, specific-
Table 1 – Overview of studies analysing the diagnostic performance of visual evaluation of whole-body diffusion-weighted imaging (WB-DWI) with or without additional
standard MRI sequences for primary whole-body tumour staging. When studies included multiple independent observers, mean scores are given. All results are per lesion
results, except for the studies by Ohno and Fischer, for which the per patient results are given.
Author Year N No readers Aim Reference standard MRI only DWI only MRI + DWI
Sens Spec Sens Spec Sens Spec
Chen et al.55 2010 56 2 (C) M-staging in NSCLC Histology and/or P6 months imaging FU – – 91 92 – –
Fischer et al.51 2010 64 2 (C) Detection of various
malignant tumours
18FDG-PET/CT 85 81 88 69 96 75
Goudarzi et al.47 2009 29 2 (C) Detection of bone mets
from various primaries
MRI, CT and/or P3 months FU – – – – 89 –
Gutzeit et al.45 2010 36 2 (I) Detection of bone mets from
prostate and breast ca.
Two reader consensus from scintigraphy, CT, MRI,
PET, PET/CT,
conventional radiography and/or ultrasound
– – 82 99 – –
Heusner et al.48 2010 20 2 (C) M-staging in breast cancer Histology, concordant DWI and 18FDG-PET findings,
MRI, CT and scintigraphy
– – – – 86 67
Komori et al.33 2007 16 2 (C) Detection of various
malignant tumours
Histology and/or P6 months clinical and imaging FU – – – – 93 –
Lin et al.78 2010 15 2 (C) Staging of large B-Cell lymphoma 18FDG-PET/CT – – 81 100 – –
Lambregts et al.77 2010 15 2 (C) M-staging in rectal cancer Histology, 18FDG-PET/CT, and/or P6 months
clinical and imaging FU
– – 81 – – –
Laurent et al.56 2009 35 2 (C) M-staging in malignant
melanoma
Histology, 18FDG-PET/CT, MRI and/or tumour markers – – – – 83 98
Nakanishi et al.46 2007 30 2 (I) Detection of bone mets
from various primaries
P6 months FU with MRI, CT, radiography
and/or scintigraphy
88 – – – 96 –
Ohno et al.54 2008 203 2 (I) M-staging in NSCLC Biopsy, radiography, MRI, 18FDG-PET/CT
and P12 months clinical FU
60 92 58 88* 70 92**
Stecco et al.49 2009 29 2 (I) Detection of various
malignant tumours
18FDG-PET/CT – – 88 99 – –
Takenaka et al.53 2009 115 2 (I) Detection of bone
mets from NSCLC
Biopsy and/or P12 months FU with
MRI, 18FDG-PET/CT and scintigraphy
73 96 96* 94* 96* 96**
Abbreviations: NSCLC = Non-small cell lung cancer; M-staging = metastases staging; mets = metastases; FU = Follow-up; (I) = independent; (C) = in consensus; Sens = sensitivity; Spec = specificity;
18FDG-PET = 2-Fluorine-18-fluoro-2-deoxy-D-glucose positron emission tomography; CT = Computed Tomography; MRI = Magnetic Resonance Imaging; DWI = Diffusion-weighted Imaging.
* Indicates a significant difference compared with MRI only.
** Indicates a significant difference compared with DWI only.
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uation of bone metastases.45,48 Goudarzi et al. confirmed in
their study that many benign bone lesions and normal struc-
tures demonstrated high signal intensity on DWI, again sug-
gesting a limited specificity.47
Some authors did not focus on a homogeneous study pop-
ulation as described above, but included patients with a vari-
ety of primarymalignancies.33,49–51 Most of these studies used
18FDG-PET/CT as the reference standard. A high concordance
between WB-DWI and PET/CT for detection of lesions was
generally reported,33,49 although Lichy et al. found that PET/
CT was able to identify several mediastinal lymph node
metastases, which were missed with WB-DWI.50 Further-
more, Fischer et al. showed a low sensitivity of only 19% for
WB-DWI, when looking specifically at the detection of lung
metastases. Moreover, when they compared WB-DWI with
standard WB-MRI, relatively many false positives were
encountered with WB-DWI, resulting in a lower overall PPV
for WB-DWI (84%) than for standard MRI (93%).51
Different studies have shown that a combination of DWI
and anatomical MR imaging (WB-MRI/DWI) provides higher
accuracy than the use of WB-MRI or WB-DWI as stand alone
techniques. Tsushima showed in a study of 110 abdominal
examinations that DWI as a stand alone technique resulted
in a sensitivity and specificity of only 72% and 59%, respec-
tively, for detection of malignant lesions. When the anatomi-
cal MR images and DWI were combined, results improved to
90% and 82%. The combination of MRI + DWI was also signif-
icantly better than the use of standard MRI only (sensitivity
80%, specificity 69%).52 This finding was confirmed by three
other groups who all reported a superior diagnostic perfor-
mance for the combined WB-MRI/DWI as compared to each
on its own.51,53,54
The role of whole-body DWI for ADC quantification has
rarely been studied. Feuerlein et al. applied WB-DWI to mea-
sure ADC in a group of 230 patients with a variety of benign
and malignant abdominal lesions.27 They observed lower
ADC values for themalignant tumours, but there was an over-
lap in ADC with the benign lesions and the difference was not
statistically significant (P = 0.72). This finding can probably
partly be attributed to the fact that the study included a very
heterogeneous group of lesions (including liver, pancreas,
colorectal and gynaecological lesions), for which sub analyses
were not provided.
4.3. WB-DWI versus 18FDG-PET
DWI and PET are both functional imaging techniques, but
their mechanisms of action differ considerably. Whereas
PET uses differences in the glucose metabolism between be-
nign and malignant tissues, DWI analyses differences in tis-
sue cellular structure. Therefore, reasons for false positivity
and false negativity will differ between the two techniques.
PET is mainly hampered by its limited spatial resolution and
problems in interpreting areas of inflammation. DWI on the
other hand, mainly suffers from false positivity in high-cellu-
lar organs or lesions.
Few studies have systematically compared WB-DWI with
18FDG-PET. The key findings of these reports are summarised
in Table 2. The main methodological problem is the lack of atrue gold standard, since generally not all lesions can be his-
tologically confirmed. In most studies, the reference standard
consists of a combination of clinical and imaging examina-
tions and long-term follow-up. Three studies compared
whole-body DWI and 18FDG-PET/CT for M-staging in patients
with non-small cell lung cancer (NSCLC).53–55 All reported
equal results for WB-DWI and PET/CT, with sensitivities and
specificities for both techniques ranging between 63–97%
and 92–98%, respectively. Laurent et al. found superior sensi-
tivity for WB-DWI compared to PET/CT for M-staging in pa-
tients with malignant melanoma.56 Komori et al. analysed a
group with a variety of primary malignancies and reported a
sensitivity of 93% for WB-DWI for malignant tumour detec-
tion versus 82% for PET/CT. In addition to visual evaluation,
they also compared quantitative measurements of 18FDG-
PET and DWI: whereas the standardised uptake value (SUV)
of PET showed significant differences between malignant le-
sions and reference organs, ADC was not able to discriminate
between normal and malignant tissue.33 Heusner et al. com-
pared WB-DWI to PET/CT for whole-body staging in 20 pa-
tients with breast cancer.48 Sensitivity was equally high for
both modalities, but specificity and PPV were significantly
better for PET/CT. The main reasons for false positivity on
DWI were benign lymph nodes and bone lesions.5. WB-imaging for colorectal cancer staging
Because MRI plays an important role in the local staging of
colorectal cancer, it is interesting to explore whether MRI
(and/or DWI) can also be used for whole-body tumour staging
in this patient group. At present, the role of MRI is, however,
not yet established, whereas the roles of CT and 18FDG-PET
are much more consolidated. 18FDG-PET has proven to be
more sensitive than CT for both local and distant tumour
detection. Reported sensitivities and specificities for 18FDG-
PET range from 78–100% and 50–100%, respectively,57,58
whereas for CT these range between 32–100% and 58–
98%.57,59,60 Since its launch in clinical practice about a decade
ago, hybrid 18FDG-PET/CT has increasingly been shown to be
superior in performance compared to either CT or 18FDG-PET
as a stand alone modality, with sensitivities and specificities
ranging from 80–100% and 67–100%, respectively.61,62 Never-
theless PET/CT is not incorporated in the guidelines as a pri-
mary staging modality of first choice and CT is still the
recommended modality. The use of PET/CT is, however, justi-
fied and proven more beneficial than CT for the detection of
extrahepatic metastases when curative liver surgery is con-
sidered in patients with liver metastases. As such, PET/CT
can reduce the number of unnecessary laparotomies and lim-
it the high treatment costs.63–65 The main role of PET/CT in
patients with colorectal cancer at present consists of (1)
excluding the presence of extrahepatic metastases in patients
who are potential candidates for curative resection of isolated
liver metastasis, (2) characterising equivocal findings on CT
and (3) detecting recurrent tumour in patients with a clinical
suspicion and rising carcino-embryonic antigen (CEA) levels
during follow-up after rectal cancer surgery.66,67 In the latter
setting, 18FDG-PET has a sensitivity of nearly 100% and a spec-
ificity of 71%.67
Fig. 3 – WB-DWI for the detection of metastatic liver lesions.
WB-DWI [a] and 18FDG-PET images [b] of a 65 year old
female patient with a tumour in the rectum (*) and several
hepatic metastases (arrowheads). Both the primary tumour
and the metastases are clearly visible on WB-DWI.
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So far, there is no evidence for the combined use of MRI/DWI
as a whole-body primary staging modality in colorectal can-
cer. Two studies have investigated the use of conventional
WB-MRI without DWI, but both focussed on the detection of
recurrent tumour during follow-up and not on primary stag-
ing.61,68 Some studies exist that used DWI in a dedicated pro-
tocol for either local or distant staging in colorectal cancer
patients and have shown promise for DWI in the primary
detection of colorectal tumours,69–71 the detection of colorec-
tal hepatic metastases,72,73 for lymph node staging32,74,75 and
for the evaluation of tumour response after neoadjuvant che-
mo- or chemoradiation treatment.18–21,23–25,76 However, no re-
ports exist on the use of DWI as a single whole-body staging
modality in colorectal cancer. In a feasibility study, we per-
formed WB-DWI in a group of 15 patients with known colo-
rectal cancer and suspected distant metastases using a
combination of histology, 18FDG-PET/CT and/or follow-up
imaging as the reference standard,77 Additionally, we in-
cluded a control group of 6 healthy volunteers. The WB-DWI
protocol was performed at a 1.5T MR unit (Intera; Philips Med-
ical Systems, Best, The Netherlands) using the built-in quad-
rature body coil. A DWIBS-sequence was acquired in 6 stacks
(b-values 0,800 s/mm2, TR/TE 3717/70 ms, EPI factor 95, 8 NSA,
2.93 · 2.96 · 5.00 acquisition voxel size, 26 slices per stack,
2.06 min acquisition time per stack), that were aligned as 3D
maximum intensity projections (MIP) for image evaluation
(Fig. 1). Overall sensitivity of WB-DWI as a single modality
for detection of malignant lesions was 81%; all primary colo-
rectal tumours were detected, 77% of the liver metastases
(Fig. 3), 72% of the distant nodal metastases (Fig. 2) and 75%
Fig. 4 – WB-DWI for the evaluation of metastatic lung disease. Coronal [a] and sagittal [b] WB-DWI reconstruction of a 88 year
old male patient with pulmonary metastases originating from a primary tumour in the rectum (*), which corresponds with a
rectal tumour as seen on T2-weighted MRI [e]. In the thorax there are two high signal intensity lesions, suggestive for lung
metastases (arrowheads), which correspond with a suspicious area visible adjacent to the aorta (circle) on the chest X-ray [c].
On the chest CT [d] it was confirmed that the high signal intensity lesions on DWI corresponded with two metastases in the
left lung (arrows). There was another small metastasis visible in the right lung [f] that could not be visualised with DWI. Such
small nodular metastases may be beyond the detection level of WB-DWI.
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teers several pronounced lymph nodes were also seen on
DWI, mainly in the axillary and inguinal regions (Fig. 2). This
indicates that DWI visualises benign and malignant nodes
with similar high signal, resulting in limited specificity. All to-
gether, the lesion detection of WB-DWI was already promis-
ing (81%), using nowadays MR equipment and available
software. With advancing MR technology it is, however, ex-
pected that DWI techniqueswill improve. Furthermore, proto-
col optimisation and the combined use of functional WB-DWI
and anatomical MR imaging may contribute to a further
improvement in diagnostic performance.6. Conclusions
Whole-body tumour staging using CT, 18FDG-PET and hybrid
PET/CT is already widespread incorporated in daily practice.
Newer techniques, like whole-body MRI – and in particular
diffusion-weighted MRI – are, however, emerging. Results
from various cancer studies, as well as our preliminary results
in colorectal cancer are encouraging: sensitivity of WB-DWI
for malignant lesion detection is promisingly high. Encourag-
ing specificities have also been reported, although false posi-
tives are known to occur, particularly in the evaluation of
lymph nodes and bone lesions. Especially for patients with
rectal cancer, in whom local staging with MRI is recom-
mended and in many countries even mandatory, the avail-
ability of a cost-effective single modality tool for both local
and distant staging justifies further investigation on DWI.
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